Login to Your Account



Clinic Roundup


Wednesday, September 7, 2011
Vertex Pharmaceuticals Inc., of Cambridge, Mass., said that its JAK3 inhibitor, VX-509, showed positive results in a Phase IIa trial in rheumatoid arthritis. The 12-week study met both of its primary endpoints: improvement in symptoms, and improvement from baseline disease activity score.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription